The Acton, Massachusetts–based company said the updates to its tubeless, wearable automated insulin delivery patch pump’s algorithm include a new benchmark in tubeless diabetes technology with a lower, 100 mg/dL target glucose option. It also delivers a more seamless automated experience.

Omnipod 5 is the first FDA-cleared tubeless automated insulin delivery system available on the market. It communicates with a CGM to proactively correct for glucose highs every five minutes and protect against lows with insulin dosing.